MedTrace Logo

Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer

NCT00363285 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2013-08-26

No results posted yet for this study

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether giving cyproterone acetate continuously is more effective than giving cyproterone acetate after tumor progression in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying cyproterone acetate to compare how well it works when given continuously or after tumor progression in treating patients with newly diagnosed stage III or stage IV prostate cancer.

Conditions

Interventions

BIOLOGICAL

gonadotrophin releasing hormone

DRUG

cyproterone acetate

PROCEDURE

quality-of-life assessment

Sponsors & Collaborators

  • St. Bartholomew's Hospital

    lead OTHER

Principal Investigators

  • R. T. Oliver, MD · St. Bartholomew's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
79 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00363285 on ClinicalTrials.gov